Anti-Spike IgG persistence | Third dose vaccine IgG response | ||
Patients, N=33* | Healthy volunteers, N=26* | Patients, N=32* | |
S1 IgG positive | 29/33 (88%) | 24/26 (92%) | 6/32 (19%) |
Quantiferon positive | 14/32 (44%) | 11/16 (69%) | 10/31 (32%) |
Double positive | 14 (32 (44%) | 10/16 (62%) | 2/31 (6.5%) |
Double negative | 4/32 (12% | 1/16 (6.2%) | 17/31 (55%) |
Patients received two or three doses of mRNA vaccines, and healthy volunteers received two doses of mRNA vaccines against SARS-CoV-2
*n(N (%).